1. Home
  2. NUVL vs SYM Comparison

NUVL vs SYM Comparison

Compare NUVL & SYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$99.24

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Logo Symbotic Inc.

SYM

Symbotic Inc.

HOLD

Current Price

$48.65

Market Cap

7.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
SYM
Founded
2017
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
7.5B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NUVL
SYM
Price
$99.24
$48.65
Analyst Decision
Strong Buy
Hold
Analyst Count
15
13
Target Price
$135.33
$57.31
AVG Volume (30 Days)
443.1K
1.7M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
N/A
$2,246,922,000.00
Revenue This Year
N/A
$24.75
Revenue Next Year
$1,064.25
$27.90
P/E Ratio
N/A
$2,661.00
Revenue Growth
N/A
25.65
52 Week Low
$55.54
$16.32
52 Week High
$113.02
$87.88

Technical Indicators

Market Signals
Indicator
NUVL
SYM
Relative Strength Index (RSI) 42.84 34.55
Support Level $98.65 $48.60
Resistance Level $107.13 $50.14
Average True Range (ATR) 4.05 2.69
MACD -0.31 -0.29
Stochastic Oscillator 19.28 0.43

Price Performance

Historical Comparison
NUVL
SYM

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About SYM Symbotic Inc.

Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.

Share on Social Networks: